William Boston
Family Health · Greenwell Springs, LANPI 1487063590
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 475 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations.
Across 475 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$985
- Lilly USA, LLC$839
- Lundbeck LLC$364
- Corium, LLC$331
- AstraZeneca$314
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,265100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 97 | $1,335 |
| Novo Nordisk | 87 | $985 |
| Lilly USA, LLC | 58 | $839 |
| Lundbeck LLC | 21 | $364 |
| Corium, LLC | 25 | $331 |
| AstraZeneca | 18 | $314 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $290 |
| GSK | 14 | $245 |
| Amgen | 18 | $237 |
| Pfizer | 15 | $230 |
| Boehringer Ingelheim | 11 | $187 |
| Axsome Therapeutics, Inc. | 8 | $182 |
| Otsuka America Pharmaceutical, Inc. | 10 | $168 |
| Abbott | 7 | $152 |
| Teva Pharmaceuticals USA, Inc. | 6 | $146 |
| Vanda Pharmaceuticals Inc. | 4 | $137 |
| Tolmar, Inc. | 6 | $106 |
| Antares Pharma, Inc. | 5 | $102 |
| Shield Therapeutics Inc | 6 | $96 |
| Merz North America, Inc. | 2 | $96 |
| Eisai Inc. | 5 | $92 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $78 |
| Avanir Pharmaceuticals, Inc. | 4 | $71 |
| Exact Sciences | 4 | $69 |
| Biohaven Pharmaceuticals, Inc. | 4 | $62 |
| Adlon Therapeutics L.p. | 4 | $57 |
| Merck | 3 | $48 |
| Tris Pharma Inc | 2 | $43 |
| Bausch Health US, LLC | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Johnson & Johnson | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Qiagen, LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
Too few family health providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 223 | $341,034 |
| MounjaroTirzepatide | 88 | $142,435 |
| JardianceEmpagliflozin | 64 | $72,549 |
| LinzessLinaclotide | 47 | $32,303 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $31,734 |
| RybelsusSemaglutide | 16 | $24,513 |
| EliquisApixaban | 27 | $21,895 |
| JanuviaSitagliptin Phosphate | 14 | $13,692 |
| TrulicityDulaglutide | 14 | $12,894 |
| Repatha SureclickEvolocumab | 13 | $12,818 |
| TrintellixVortioxetine Hydrobromide | 16 | $11,069 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,619 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 128 | $3,885 |
| Ventolin HfaAlbuterol Sulfate | 28 | $3,562 |
| Gabapentin | 126 | $2,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $985 | $365,546239 claims |
| Lilly USA, LLCMounjaro, Trulicity | $839 | $155,329102 claims |
| Boehringer IngelheimJardiance | $187 | $72,54964 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $245 | $36,35343 claims |
| AbbVieLinzess, Synthroid | $1,335 | $33,61178 claims |
| PfizerEliquis | $230 | $21,89527 claims |
| MerckJanuvia | $48 | $13,69214 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $290 | $11,06916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other family health in Greenwell Springs
- Lucy DouglasRuston$3K
- Linda FordJena$3K
- Beth LagardeThibodaux$1K
- Charlene BornePearl River$417
- Lisa JosephFort Polk$350
- Andrea MooreShreveport$329
- Dianna WadsworthSlidell$225
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.